MX2021006930A - Construcciones de proteínas de fusión para enfermedades asociadas al complemento. - Google Patents

Construcciones de proteínas de fusión para enfermedades asociadas al complemento.

Info

Publication number
MX2021006930A
MX2021006930A MX2021006930A MX2021006930A MX2021006930A MX 2021006930 A MX2021006930 A MX 2021006930A MX 2021006930 A MX2021006930 A MX 2021006930A MX 2021006930 A MX2021006930 A MX 2021006930A MX 2021006930 A MX2021006930 A MX 2021006930A
Authority
MX
Mexico
Prior art keywords
fusion protein
protein constructs
complement
associated disease
complement associated
Prior art date
Application number
MX2021006930A
Other languages
English (en)
Inventor
Susan L Kalled
Justin Andrew Caravella
Michael Steven Curtis
Michael Storek
Shelia Marie Violette
Kelly C Fahnoe
Cheng Ran Huang
Ellen Garber Stark
Frederick Robbins Taylor
Vernon Michael Holers
Original Assignee
Q32 Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q32 Bio Inc filed Critical Q32 Bio Inc
Publication of MX2021006930A publication Critical patent/MX2021006930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan construcciones de proteínas de fusión que pueden unirse a un antígeno asociado al complemento, que comprenden un resto de direccionamiento y una proteína del modulador del complemento, o un fragmento de la misma o una variante de la misma; el resto de direccionamiento es un anticuerpo o un fragmento de unión al antígeno del mismo, en algunos ejemplos; se proporcionan además métodos para usar las construcciones de proteínas de fusión, por ejemplo, en el tratamiento de afecciones mediadas por el complemento.
MX2021006930A 2018-12-11 2019-12-11 Construcciones de proteínas de fusión para enfermedades asociadas al complemento. MX2021006930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Publications (1)

Publication Number Publication Date
MX2021006930A true MX2021006930A (es) 2021-11-17

Family

ID=71076704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006930A MX2021006930A (es) 2018-12-11 2019-12-11 Construcciones de proteínas de fusión para enfermedades asociadas al complemento.

Country Status (11)

Country Link
EP (1) EP3893916A4 (es)
JP (2) JP7444886B2 (es)
KR (1) KR20210148076A (es)
CN (1) CN113660944A (es)
AU (2) AU2019398214C1 (es)
CA (1) CA3123004A1 (es)
IL (1) IL283841A (es)
MA (1) MA54468A (es)
MX (1) MX2021006930A (es)
SG (1) SG11202106073QA (es)
WO (1) WO2020123662A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963830T3 (es) * 2016-10-20 2024-04-02 Harvard College Ensayos in vitro y basados en células para medir la actividad de las neurotoxinas botulínicas
US20220305133A1 (en) * 2019-06-12 2022-09-29 CSL Innovation Pty., Ltd. Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN118005802A (zh) * 2022-11-10 2024-05-10 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
CN100389826C (zh) * 2001-12-28 2008-05-28 协和发酵工业株式会社 关节炎的治疗药
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011163412A1 (en) * 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US8940490B2 (en) 2010-11-29 2015-01-27 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
JP6563815B2 (ja) * 2013-01-23 2019-08-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 天然抗体に由来する構築物を標的化すること及びその使用
JP6702866B2 (ja) * 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015105973A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
BR112016022814A8 (pt) * 2014-04-01 2021-07-06 Rubius Therapeutics Inc composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
JP6817211B2 (ja) * 2015-01-23 2021-01-20 サノフイＳａｎｏｆｉ 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体

Also Published As

Publication number Publication date
WO2020123662A2 (en) 2020-06-18
JP2024059791A (ja) 2024-05-01
IL283841A (en) 2021-07-29
CA3123004A1 (en) 2020-06-18
SG11202106073QA (en) 2021-07-29
AU2019398214C1 (en) 2024-03-28
AU2019398214A1 (en) 2021-07-01
KR20210148076A (ko) 2021-12-07
AU2019398214B2 (en) 2023-11-23
EP3893916A2 (en) 2021-10-20
AU2024201109A1 (en) 2024-03-14
MA54468A (fr) 2022-04-13
CN113660944A (zh) 2021-11-16
EP3893916A4 (en) 2023-03-29
JP2022512234A (ja) 2022-02-02
WO2020123662A3 (en) 2020-07-23
JP7444886B2 (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2021006930A (es) Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
IL280467A (en) Antibody constructs for CLDN18.2 and CD3
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX2020000960A (es) Anticuerpos anti-tigit.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
AR105267A1 (es) Anticuerpos de unión a tau
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2021008216A (es) Anticuerpos anti-tigit.
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2021006389A (es) Anticuerpo cd3 y uso farmaceutico del mismo.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
CR20210324A (es) Anticuerpos anti-pmel 17 y conjugados de los mismos
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células